These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36174768)

  • 1. Endothelial and vascular smooth muscle dysfunction in hypertension.
    de Oliveira MG; Nadruz W; Mónica FZ
    Biochem Pharmacol; 2022 Nov; 205():115263. PubMed ID: 36174768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
    McCoy EK; Lisenby KM
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoids but not mineralocorticoids modulate endothelin-1 and angiotensin II binding in SHR vascular smooth muscle cells.
    Provencher PH; Saltis J; Funder JW
    J Steroid Biochem Mol Biol; 1995 Mar; 52(3):219-25. PubMed ID: 7696142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries.
    Dohi Y; Criscione L; Pfeiffer K; Lüscher TF
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):372-9. PubMed ID: 7528292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen-activated protein kinase activity regulation role of angiotensin and endothelin systems in vascular smooth muscle cells.
    Kubo T; Ibusuki T; Chiba S; Kambe T; Fukumori R
    Eur J Pharmacol; 2001 Jan; 411(1-2):27-34. PubMed ID: 11137855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme inhibitors and vascular protection in hypertension.
    Ruschitzka F; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 1():S3-12. PubMed ID: 10499558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
    Mason RP
    Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
    Sutanto H; Dobrev D; Heijman J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelin in hypertension.
    Schiffrin EL
    Vascul Pharmacol; 2005 Jun; 43(1):19-29. PubMed ID: 15955745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
    Kowala MC; Murugesan N; Tellew J; Carlson K; Monshizadegan H; Ryan C; Gu Z; Kane B; Fadnis L; Baska RA; Beyer S; Arthur S; Dickinson K; Zhang D; Perrone M; Ferrer P; Giancarli M; Baumann J; Bird E; Panchal B; Yang Y; Trippodo N; Barrish J; Macor JE
    J Pharmacol Exp Ther; 2004 Apr; 309(1):275-84. PubMed ID: 14718594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug.
    Chrysant SG
    Expert Opin Drug Saf; 2021 Jun; 20(6):635-640. PubMed ID: 33734912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice.
    Groneberg D; König P; Wirth A; Offermanns S; Koesling D; Friebe A
    Circulation; 2010 Jan; 121(3):401-9. PubMed ID: 20065162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin as a regulator of cardiovascular function in health and disease.
    Haynes WG; Webb DJ
    J Hypertens; 1998 Aug; 16(8):1081-98. PubMed ID: 9794709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model.
    Crassous PA; Couloubaly S; Huang C; Zhou Z; Baskaran P; Kim DD; Papapetropoulos A; Fioramonti X; Durán WN; Beuve A
    Am J Physiol Heart Circ Physiol; 2012 Sep; 303(5):H597-604. PubMed ID: 22730391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats.
    Bolterman RJ; Manriquez MC; Ortiz Ruiz MC; Juncos LA; Romero JC
    Hypertension; 2005 Oct; 46(4):943-7. PubMed ID: 16087785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease.
    Mazzuca MQ; Khalil RA
    Biochem Pharmacol; 2012 Jul; 84(2):147-62. PubMed ID: 22484314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide inhibition and renal alterations.
    Jover B; Mimran A
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S65-70. PubMed ID: 11811381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.